FZD7 (frizzled class receptor 7) functions as a transmembrane receptor for Wnt signaling pathways, playing critical roles in cancer progression and cellular development. The protein serves as a receptor for various Wnt ligands, including WNT2, WNT7A, and WNT11, mediating both canonical and non-canonical Wnt signaling 1 2 3. FZD7 activates downstream pathways including β-catenin signaling and FZD7/JAK1/STAT3 signaling, promoting tumor cell proliferation, invasion, and metastasis 2 4. In melanoma, WNT11-FZD7-DAAM1 signaling supports tumor-initiating abilities and amoeboid invasion through activation of Rho-ROCK1/2-Myosin II pathways 3. The receptor is significantly overexpressed in multiple cancer types including gastric cancer, colorectal cancer, intrahepatic cholangiocarcinoma, head and neck squamous cell carcinoma, and endometriosis 5 4 2 6. Therapeutically, soluble FZD7 decoy receptors can competitively inhibit Wnt signaling and reduce tumor cell viability, suggesting FZD7 as a potential therapeutic target 5 7. The protein also shows zonated expression patterns in hepatocytes, indicating roles in normal tissue organization 8.